Table V.
Risk of head and neck squamous cell carcinoma from combined exposure to any XRCC1 polymorphism and smoking, stratified by HPV16 serology
| HPV16 serology |
≥20 Pack- years |
XRCC1 variant allele1 |
Cases n=485 (%) |
Controls n=549 (%) |
OR2 | (95% CI) |
Pinteraction, pack-yrs and XRCC1 |
|---|---|---|---|---|---|---|---|
| Negative | No | No | 38 (7.8) | 73 (13.3) | referent | 0.04 | |
| Yes | 72 (14.8) | 225 (41.0) | 0.70 | (0.42-1.17) | |||
| Yes | No | 59 (12.2) | 64 (11.7) | 1.62 | (0.90-2.93) | ||
| Yes | 171 (35.3) | 129 (23.5) | 2.25 | (1.35-3.75) | |||
| Positive | No | No | 21 (4.3) | 9 (1.6) | referent | 0.89 | |
| Yes | 51 (10.5) | 27 (4.9) | 0.84 | (0.33-2.14) | |||
| Yes | No | 22 (4.5) | 6 (1.1) | 1.11 | (0.33-3.82) | ||
| Yes | 51 (10.5) | 16 (2.9) | 1.05 | (0.39-2.85) |
1
Had at least one variant allele in an XRCC1 polymorphism (194Trp, 280Gln, or 399Gln).
2
ORs controlled for age, sex, race, education, and alcohol consumption.